ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$38.88
+6.17%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 156.70x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.64x
- Price / sales
- 3728.61x
- Price / cash flow
- -34.70x
Enterprise value
- Enterprise value
- $25.0B
- EV / sales
- 3324.43x
- EV / EBITDA
- -87.24x
- EV / EBIT
- -18.33x
- Market cap
- $28.1B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026